This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Other leukaemias of specified cell type
CD2_OTHER_LEUKAEMIA_SPECIFIED
leukemia: A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
91 |
4. Check minimum number of eventsNone |
91 |
5. Include endpointsNone |
91 |
6. Filter based on genotype QC (FinnGen only) |
86 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF8
- Parent code in ICD-10
- C81-C96
- Name in latin
- Aliae leuc(h)aemiae typo cellulari specificato
Similar endpoints
↥List of similar endpoints to
Other leukaemias of specified cell type
based on the number of shared cases.
Similar with more cases:
- Primary_lymphoid and hematopoietic malignant neoplasms
- Liquid cancers, helper endpoint
- Malignant neoplasm
- Malignant neoplasm, wide definition for exclusion
- Neoplasms
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 86 | 47 | 39 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 55.47 | 52.99 | 58.46 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 91
- Matched controls
- 910
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
36.1
61.1
45
24
127
Kela drug reimbursment
Transplant complication
111.6
33.8
35
5
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
18.3
33.3
31
25
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
12.9
26.7
31
35
C94.0
ICD-10 Finland
Acute erythroid leukaemia
+∞
26.3
24
*
XW000
NOMESCO Finland
Bone marrow biopsy
36.1
25.9
33
14
C94.7
ICD-10 Finland
Other specified leukaemias
+∞
22.9
21
*
L04AA06
ATC
mycophenolic acid; systemic
45.7
20.1
24
7
ZX120
NOMESCO Finland
Intravenous
8.7
19.6
31
51
L04AA01
ATC
[U] ciclosporin
67.2
18.9
21
*
L04AD01
ATC
ciclosporin; systemic
35.6
17.5
22
8
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
6.8
16.7
35
77
R50.9
ICD-10 Finland
Fever, unspecified
5.8
14.4
36
92
WW500
NOMESCO Finland
Blood transfusion
15.8
14.1
23
19
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
27.6
13.5
18
8
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
5.6
13.0
32
80
Z94.0
ICD-10 Finland
Kidney transplant status
44.3
12.6
15
*
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
44.3
12.6
15
*
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
44.3
12.6
15
*
C92.0
ICD-10 Finland
Acute myeloblastic leukaemia [AML]
74.9
11.9
13
*
L04AD02
ATC
tacrolimus; systemic
74.9
11.9
13
*
J01MA12
ATC
levofloxacin; systemic
5.0
11.9
35
101
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
5.8
11.6
26
59
TK800
NOMESCO Finland
Hemodialysis
23.9
11.6
16
8
C03CA01
ATC
furosemide; systemic
4.5
11.5
49
188
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.7
11.1
64
305
Z3226
NOMESCO Finland
Physiotherapist
4.6
10.9
36
113
Z49.1
ICD-10 Finland
Extracorporeal dialysis
68.3
10.9
12
*
C91.0
ICD-10 Finland
Acute lymphoblastic leukaemia [ALL]
68.3
10.9
12
*
Z3231
NOMESCO Finland
Registered nurse
4.2
10.6
47
183
C94.1
ICD-10 Finland
Chronic erythremia
+∞
10.6
10
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
5.3
10.6
26
64
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
23.3
10.2
14
7
A11CC03
ATC
alfacalcidol; systemic
29.9
10.1
13
5
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
5.9
10.1
21
44
H02AB09
ATC
hydrocortisone; systemic
13.6
10.1
17
15
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
61.8
9.9
11
*
H02AB04
ATC
methylprednisolone; systemic
4.7
9.8
29
83
M04AA01
ATC
allopurinol; systemic
5.2
9.7
24
59
B03XA01
ATC
erythropoietin; parenteral
111.1
9.6
10
*
Z2446
NOMESCO Finland
Social worker
5.8
9.6
20
42
C94.4
ICD-10 Finland
Acute panmyelosis with myelofibrosis
+∞
9.5
9
*
C94.2
ICD-10 Finland
Acute megakaryoblastic leukaemia
+∞
9.5
9
*
R4110
NOMESCO Finland
Physiotherapy
3.9
9.3
42
163
ZX108
NOMESCO Finland
Inhalation
41.2
9.2
11
*
A12AA04
ATC
calcium carbonate; oral
41.2
9.2
11
*
TGC00
NOMESCO Finland
Bronchial lavation
21.3
9.2
13
7
J01MA14
ATC
moxifloxacin; systemic
5.7
9.1
19
40
L03AA02
ATC
filgrastim; parenteral
11.9
9.0
16
16
L04AX01
ATC
azathioprine; systemic
11.9
9.0
16
16
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
55.5
8.9
10
*
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
55.5
8.9
10
*
N18.0
ICD-10 Finland
End-stage renal disease
55.5
8.9
10
*
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
10.2
8.8
17
20
L01BB02
ATC
mercaptopurine; oral
30.9
8.7
11
*
C94.5
ICD-10 Finland
Acute myelofibrosis
+∞
8.5
8
*
6BA02, ,
NOMESCO Finland
+∞
8.5
8
*
Z94.1
ICD-10 Finland
Heart transplant status
+∞
8.5
8
*
D47.1
ICD-10 Finland
Chronic myeloproliferative disease
+∞
8.5
8
*
Z3229
NOMESCO Finland
Other healthcare associate professional
5.3
8.4
19
43
KA2AE
NOMESCO Finland
Ultrasound examination transplanted kidney
37.0
8.3
10
*
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
10.0
8.2
16
19
Z2221
NOMESCO Finland
Medical doctor
3.6
8.2
41
168
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
11.0
8.2
15
16
ZXE10
NOMESCO Finland
More than one and less than three hours
3.5
7.8
46
208
D07AB08
ATC
desonide; topical
5.0
7.7
19
46
190
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
86.9
7.5
8
*
A05AA02
ATC
ursodeoxycholic acid; oral
17.6
7.4
11
7
TAB00
NOMESCO Finland
Lumbar puncture
8.2
7.4
16
23
J02AC03
ATC
voriconazole; systemic
+∞
7.4
7
*
TPH04
NOMESCO Finland
Cathetrisation of vein
3.6
7.3
33
125
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
8.7
7.2
15
20
GD1AD
NOMESCO Finland
Thorax CT examination
8.7
7.2
15
20
J05AB01
ATC
aciclovir; systemic
3.5
7.2
33
126
ZXD05
NOMESCO Finland
Urgent procedure
3.3
7.0
39
169
N18.8
ICD-10 Finland
Other chronic renal failure
18.5
6.9
10
6
9835/3-C42.1
ICD-O-3
Precursor cell lymphoblastic leukemia, NOS, of bone marrow
43.4
6.9
8
*
137
Kela drug reimbursment
Uraemia requiring dialysis
24.7
6.8
9
*
TPH30
NOMESCO Finland
Insertion of central venous catheter through periferal vein
24.7
6.8
9
*
B03XA02
ATC
darbepoetin alfa; parenteral
13.7
6.8
11
9
TPX10
NOMESCO Finland
Implantation of vascular injection port
11.3
6.8
12
12
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
7.0
6.7
16
27
9961/3-C42.1
ICD-O-3
Primary myelofibrosis of bone marrow
74.9
6.5
7
*
KA1MN
NOMESCO Finland
Glomerular filtration rate (GFR) Isotope mesurement
74.9
6.5
7
*
J05AB11
ATC
valaciclovir; oral
3.8
6.5
24
79
A41.5
ICD-10 Finland
Sepsis due to other Gram-negative organisms
8.7
6.4
13
17
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
8.7
6.4
13
17
20700
ICD-8 Finland
Other and unspecified leukaemia, Leukaemia, acute
+∞
6.3
6
*
196
Kela drug reimbursment
Paricalcitol and cinacalcet
+∞
6.3
6
*
C95.0
ICD-10 Finland
Acute leukaemia of unspecified cell type
+∞
6.3
6
*
B07.9
ICD-10 Finland
Verruca simplex
11.2
6.2
11
11
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
43
99
7.34
19.95
21.6
6.9
1.10
1.10
mmol/l
0.04
43
93
26
45
7.69
15.46
3.4
1.8
—
—
—
0
0
35
84
6.15
15.06
2.2
1.5
—
—
—
0
0
41
119
5.45
14.16
3.9
1.7
—
—
—
0
0
34
85
5.79
13.88
2.3
1.5
—
—
—
0
0
41
128
5.01
12.79
11.3
3.9
0.80
0.83
mmol/l
0.85
41
118
20
15
16.69
12.68
1.5
1.3
—
—
—
0
0
70
361
5.07
10.78
25.4
7.2
1.21
1.22
mmol/l
0.40
64
311
31
99
4.23
9.00
5.5
2.3
2.09
2.39
g/l
1.33
31
91
17
25
8.10
7.74
2.2
1.2
—
—
—
0
0
30
104
3.81
7.65
5.7
2.3
12.17
15.24
umol/l
1.32
30
98
18
42
5.10
7.62
2.3
1.5
—
—
—
0
0
17
27
7.48
7.37
4.3
2.5
88.71
84.70
%
0.20
17
27
14
16
10.11
7.36
5.4
1.8
—
—
—
0
0
14
16
10.11
7.36
5.4
1.8
—
—
—
0
0
73
451
4.13
7.35
30.7
9.6
3.80
4.07
e9/l
0.33
68
386
10
5
22.17
7.31
3.8
1.2
—
—
—
0
0
15
21
8.32
7.05
5.5
1.5
—
—
—
0
0
16
26
7.23
6.84
5.4
1.7
—
—
—
0
0
16
26
7.23
6.84
6.1
1.7
—
—
—
0
0
25
84
3.72
6.58
11.1
6.4
104.64
104.14
mmol/l
0.21
25
84
51
274
2.96
6.06
7.6
3.3
—
—
—
0
0
9
6
16.43
6.04
10.0
4.0
—
—
—
0
0
44
224
2.87
5.70
5.8
3.0
0.19
0.41
e6/l
0.88
39
160
32
142
2.93
5.27
4.5
2.5
0.89
0.86
e6/l
0.03
22
82
5
0
+∞
5.25
1.6
0.0
—
—
—
0
0
10
12
9.20
5.21
3.1
1.6
—
—
—
0
0
10
12
9.20
5.21
3.1
1.6
—
—
—
0
0
9
9
10.93
5.15
6.7
1.9
—
—
—
0
0
9
9
10.93
5.15
6.7
1.9
—
—
—
0
0
9
9
10.93
5.15
6.7
1.9
—
—
—
0
0
38
187
2.77
5.15
6.5
2.5
—
—
—
0
0
13
24
6.13
5.14
2.4
2.3
—
—
—
0
0
13
24
6.13
5.14
5.3
2.8
218.38
197.00
%
0.37
13
24
11
16
7.65
5.13
2.8
1.8
—
—
—
0
0
18
58
3.62
4.96
8.0
3.9
1.49
1.47
mmol/l
0.01
13
41
13
26
5.65
4.85
3.2
2.2
—
—
—
0
0
10
14
7.87
4.79
2.3
1.5
—
—
—
0
0
61
394
2.66
4.62
25.1
7.0
11.71
11.37
umol/l
0.10
61
375
9
12
8.18
4.47
6.0
1.5
—
—
—
0
0
29
133
2.73
4.41
5.6
2.6
1.43
2.05
e6/l
0.23
18
73
8
9
9.60
4.37
1.9
1.9
2.70
3.83
mg/l
—
8
9
7
6
12.48
4.35
3.6
2.7
—
—
—
0
0
7
6
12.48
4.35
3.1
1.2
—
—
—
0
0
9
13
7.54
4.27
2.9
1.4
—
—
—
0
0
10
17
6.46
4.26
2.8
1.4
—
—
—
0
0
56
359
2.46
4.14
8.8
2.7
—
—
—
0
0
9
14
7.00
4.09
6.1
1.4
—
—
—
0
0
54
344
2.40
4.00
27.1
11.8
1.26
1.17
inr
0.30
18
90
42
242
2.37
3.88
6.2
3.1
2.32
2.36
mmol/l
0.97
42
211
7
8
9.35
3.84
2.0
1.3
—
—
—
0
0
18
71
2.91
3.56
5.2
4.1
—
—
—
0
0
47
295
2.23
3.45
6.8
2.5
327.21
109.82
ug/l
3.68
47
271
16
60
3.02
3.44
6.2
3.9
51.40
68.23
ml/min/173m2
—
5
30
44
270
2.22
3.40
1.8
2.0
86.20
92.61
pmol/l
0.39
26
132
6
7
9.06
3.31
2.3
1.7
0.83
0.90
g/l
—
6
7
8
16
5.37
3.13
2.9
1.7
—
—
—
0
0
36
210
2.18
3.10
6.1
3.8
33.20
10.13
mg/mmol
1.04
29
129
12
37
3.58
3.07
2.4
1.4
—
—
—
0
0
5
5
10.47
3.01
1.2
1.0
—
—
—
0
0
5
5
10.47
3.01
1.2
1.0
—
—
—
0
0
12
38
3.48
2.99
10.3
7.6
0.70
0.66
%
0.18
12
38
7
13
5.73
2.93
2.7
1.7
—
—
—
0
0
12
39
3.39
2.90
10.3
7.4
1.41
1.58
%
0.16
12
39
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
10
29
3.74
2.79
4.4
3.0
0.28
0.40
u/ml
—
5
20
53
369
2.04
2.78
6.7
3.3
0.00
0.00
estimate
—
10
65
8
20
4.28
2.63
1.3
1.3
—
—
—
0
0
8
20
4.28
2.63
1.3
1.3
—
—
—
0
0
8
20
4.28
2.63
1.0
1.2
—
—
—
0
0
74
592
2.34
2.59
27.0
7.5
92.97
85.14
u/l
0.51
74
552
52
368
1.96
2.52
6.8
3.2
0.00
0.00
estimate
-0.00
13
74
52
368
1.96
2.52
8.5
4.5
0.00
0.00
estimate
—
9
69
5
8
6.53
2.40
1.4
1.0
—
—
—
0
0
7
18
4.12
2.30
8.4
1.2
64.29
374.54
e6/l
—
7
13
7
18
4.12
2.30
8.4
1.1
55.00
2.31
e6/l
—
7
13
6
14
4.51
2.19
1.7
1.2
—
—
—
0
0
31
192
1.93
2.16
8.4
3.6
0.00
0.00
estimate
—
7
67
5
10
5.22
2.10
4.2
1.9
—
—
—
0
0
5
10
5.22
2.10
4.2
1.9
—
—
—
0
0
5
10
5.22
2.10
1.2
1.2
—
—
—
0
0
5
10
5.22
2.10
4.2
1.9
—
—
—
0
0
5
10
5.22
2.10
4.2
1.9
—
—
—
0
0
6
15
4.20
2.07
4.3
1.7
—
—
—
0
0
5
11
4.74
1.96
4.2
1.8
—
—
—
0
0
5
11
4.74
1.96
4.2
1.8
—
—
—
0
0
6
17
3.70
1.87
1.7
1.5
—
—
—
0
0
6
17
3.70
1.87
7.5
3.7
54.83
57.06
%
—
6
17
11
50
2.37
1.64
20.1
5.2
1.23
1.22
mmol/l
0.17
11
44
38
278
1.63
1.42
7.5
3.4
—
—
—
0
0
11
55
2.14
1.34
10.3
4.9
24.02
25.28
mmol/l
0.45
11
55
5
20
2.58
1.16
3.2
1.4
59.40
37.75
nmol/l
—
5
20
7
30
2.44
1.15
10.4
2.1
—
—
—
0
0
7
31
2.36
1.13
3.9
3.7
17.86
346.96
u/ml
—
7
24
9
52
1.81
0.95
1.8
2.7
296.89
266.51
ng/l
—
9
46
6
28
2.22
0.93
4.3
2.0
—
—
—
0
0
6
29
2.14
0.91
2.3
1.2
—
—
—
0
0
6
29
2.14
0.91
2.3
1.2
—
—
—
0
0
0
24
0.00
0.80
0.0
1.5
—
3.67
—
0
15
0
24
0.00
0.80
0.0
1.2
—
2.00
—
0
17
80
841
0.60
0.72
77.6
20.1
34.30
40.35
%
6.96
74
792
5
26
1.98
0.72
4.2
2.5
—
—
—
0
0
55
480
1.37
0.71
2.9
3.1
—
—
—
0
0
5
27
1.90
0.69
1.2
1.4
35.20
39.64
u/l
—
5
22
5
27
1.90
0.69
1.0
2.4
—
—
—
0
0
6
36
1.71
0.58
10.7
2.5
0.10
0.07
e6/l
—
6
36
6
44
1.39
0.35
2.3
1.3
—
—
—
0
0
32
281
1.21
0.33
7.6
3.6
36.58
41.31
ng/l
0.11
27
194
67
704
0.82
0.30
5.9
4.4
5.85
5.91
mmol/l
0.18
61
648
79
761
1.29
0.28
58.7
13.6
27.40
23.10
mg/l
0.82
74
578
69
658
1.20
0.26
61.2
15.7
14.59
14.65
%
0.08
69
653
53
495
1.17
0.26
6.6
3.2
54.06
50.16
u/l
0.18
53
464
7
92
0.74
0.24
1.7
2.0
—
—
—
0
0
5
39
1.30
0.23
1.8
1.8
—
—
—
0
0
11
89
1.27
0.22
16.8
6.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
5.4
—
114.50
—
0
10
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.4
—
19.95
—
0
12
17
146
1.20
0.21
1.5
1.6
—
—
—
0
0
10
115
0.85
0.11
1.1
1.3
5.24
7.91
u/ml
—
5
42
78
795
0.87
0.11
34.5
10.4
27.09
26.10
u/l
0.22
78
774
78
795
0.87
0.11
57.3
15.7
112.36
75.54
umol/l
1.97
78
795
18
197
0.89
0.11
2.6
4.0
34.54
22.18
%
—
8
99
7
84
0.82
0.07
1.6
1.8
—
—
—
0
0
11
119
0.91
0.04
1.0
1.3
17.48
41.27
iu/ml
—
5
48
70
691
1.06
0.03
4.9
4.6
2.13
1.86
mu/l
0.73
65
634
10
106
0.94
0.01
1.8
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
4.67
—
0
6
0
7
0.00
-0.00
0.0
3.1
—
47.57
—
0
7
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
67
670
1.00
-0.00
44.0
13.0
70.38
81.57
ml/min/173m2
2.26
60
525
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
13.25
—
0
8
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_OTHER_LEUKAEMIA_SPECIFIED – Other leukaemias of specified cell type
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).